BioCryst Pharmaceuticals ($BCRX)

Description

Develops oral small-molecule and injectable protein medicines for hereditary angioedema and other rare diseases, with physician-requested investigational access in eligible cases.

Related

• bluebird bioDevelops one-time gene addition treatments for rare hematologic diseases, using patients' own cells and patient support services to help…
• Karyopharm Therapeutics ($KPTI)Develops and investigates oral nuclear export inhibitor cancer therapies for patients with cancer, especially in disease areas with high…
• Liquidia ($LQDA)Develops therapies and lung drug-delivery technology for rare cardiopulmonary diseases, including pulmonary arterial hypertension,…
• WonderTxApplies extrapolative AI to drug discovery research, aiming to identify new drugs and investigate oral pill alternatives to injectable…
• Beam Therapeutics ($BEAM)Develops investigational base-editing genetic medicines and delivery technologies, including electroporation, nonviral, and viral methods,…
• Genesis TherapeuticsBuilds molecular AI models and a design platform to optimize small-molecule drug discovery and create new medicines for partners and…
• Krystal Biotech ($KRYS)Develops and delivers redosable genetic medicines, including VYJUVEK for dystrophic epidermolysis bullosa, using engineered HSV-1 vectors…
• Ionis Pharmaceuticals ($IONS)Develops RNA- and DNA-targeted medicines for people with serious diseases, with marketed therapies including TEGSEDI and WAYLIVRA for…
• Numerion LabsBuilds an AI platform that searches chemical space for novel drug-like molecules, supporting small-molecule drug discovery programs for…
• ResQ Biotech Private CompanyDevelops a living-cell discovery platform that biosynthesizes and functionally screens macrocyclic libraries to identify therapeutics that…
• Exact Sciences ($EXAS)Builds cancer tests that assess hereditary risk, screen for cancer, and analyze tumor genomics to support patients and clinicians in…
• CRISPR Therapeutics ($CRSP)CRISPR Therapeutics develops CRISPR-based gene-editing therapies across hemoglobinopathies, oncology, diabetes, and cardiovascular disease,…